|
Hear from David Baker,
Anthropic's Nathan Frey and more
Wednesday, Oct. 14, 2026 | Virtual | 11 a.m. ET
AI Day brings together a Nobel laureate designing proteins from scratch and the scientist who leads drug discovery and development research at Anthropic.
David Baker, director of the Institute for Protein Design at the University of Washington, returns to talk about the progress and challenges as de novo proteins move from the lab toward becoming drugs, and how that could lead to dramatically different types of medicines. Then, in a livestreamed fireside chat, Anthropic's Nathan Frey will discuss the company's latest advances in the life sciences and its vision for the AI future of the drug industry.
Nathan Frey
Head of Drug Discovery & Development Research
Anthropic
In-person spots are sold out. Join us online for our free virtual program, plus livestreams of select afternoon sessions.
Virtual agenda highlights: - The future of work at pharma giants*: AI leaders on scaling tech inside the largest drugmakers
- AI and genetic medicine: Can AI help scale custom gene therapies for rare disease?
- How does AI affect
human skills? Weighing productivity gains against the risk of eroding expertise
- How to build AI's biological intelligence (but not destroy us all)*: Radical Numerics on AI's promise in biology and its biosecurity risks
*Livestreamed from New York
Subbu Iyer
Head, AI & Data
Takeda
Melissa J. Moore
Co-founder
Kerna Labs and Waterfall Scientific
Travis Zack
Chief Medical Officer
OpenEvidence, Inc.
Join Endpoints' award-winning Senior Biopharma Correspondent Andrew Dunn for a day of sessions with researchers, executives and AI builders, examining what changes for them as they build the future of medicine.
Sponsorship opportunities are available. Contact Meg at mestacio@endpoints.news to learn how you can support this year's AI Day.
|
